PTEN
European Commission Approves AstraZeneca's Truqap With Faslodex in ER-Positive Breast Cancer
Truqap will be the first AKT inhibitor approved in Europe for patients with ER-positive breast cancers harboring PIK3CA, AKT1, and PTEN mutations.
AstraZeneca's Truqap Misses Primary Endpoint in Phase III Triple-Negative Breast Cancer Trial
A combination of Truqap and paclitaxel did not improve the overall survival of patients with advanced triple-negative breast cancer.
CHMP Recommends AstraZeneca's Truqap With Faslodex for Certain Breast Cancer Patients
In a Phase III trial, the Truqap-Faslodex combo reduced the risk of disease progression or death by 50 percent compared to Faslodex alone.
PTEN Mutation Syndrome Leads to Breast Cancers With Distinct Molecular Alterations
A protein-coding sequence analysis uncovered somatic mutations that distinguished breast cancers in individuals with PTEN hamartoma tumor syndrome from sporadic breast cancers.
The drug, MS21, has shown preclinically to inhibit growth of tumor cells with mutations in the PI3K/PTEN/AKT pathway.
Dec 15, 2020